At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
LY3478045 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single-and Multiple Ascending Doses of LY3478045in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY3478045, Placebo, and 1 other intervention for Healthy. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it. The study will also measure how much LY3478045 gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts: Part A (one dose) will last about six weeks and Part B (more than one dose) will last about eight weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMar 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedFeb 17, 2020
Enrollment StartMar 16, 2020
Primary CompletionJun 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.4 years ago
Interventions
LY3478045drug
Administered orally.
Placebodrug
Administered orally.
Atorvastatindrug
Administered orally.